These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 12364357

  • 1. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
    Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T.
    Hypertension; 2002 Oct; 40(4):521-7. PubMed ID: 12364357
    [Abstract] [Full Text] [Related]

  • 2. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 3. Studies on the antithrombotic action of AT1 receptor antagonists.
    Buczko W, Matys T, Pawlak R, Kucharewicz I, Chabielska E.
    Med Sci Monit; 2001 Jan; 7(4):600-5. PubMed ID: 11433183
    [Abstract] [Full Text] [Related]

  • 4. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P, Ferrario CM, Brosnihan KB.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
    Schwemmer M, Sommer O, Bassenge E.
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):301-7. PubMed ID: 11800413
    [Abstract] [Full Text] [Related]

  • 6. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M, Jiménez A, Núñez A, López-Blaya A, Farré J, Gómez J, Zalba LR, Sánchez de Miguel L, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [Abstract] [Full Text] [Related]

  • 7. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
    Chłopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ.
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):715-22. PubMed ID: 11192944
    [Abstract] [Full Text] [Related]

  • 8. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan.
    Núñez A, Gómez J, Zalba LR, Montón M, Jiménez A, Velasco S, López-Blaya A, Uriarte AC, Casado S, López-Farré A.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):175-9. PubMed ID: 11967810
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin II AT(1) receptor antagonists and platelet activation.
    López-Farré A, Sánchez de Miguel L, Montón M, Jiménez A, Lopez-Bloya A, Gómez J, Núñez A, Rico L, Casado S.
    Nephrol Dial Transplant; 2001 Jun; 16 Suppl 1():45-9. PubMed ID: 11369820
    [Abstract] [Full Text] [Related]

  • 10. Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
    Hakim A, Stanke-Labesque F, Hoffmann P, Sessa C, Caron F, Cracowski JL, Bessard G.
    J Cardiovasc Pharmacol; 2003 Jul; 42(1):42-7. PubMed ID: 12827025
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
    Nossaman BD, Baber SR, Nazim MM, Detrolio JD, Kadowitz PJ.
    Can J Physiol Pharmacol; 2007 Jul; 85(3-4):360-71. PubMed ID: 17612645
    [Abstract] [Full Text] [Related]

  • 12. Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.
    Matys T, Kucharewicz I, Pawlak R, Chabielska E, Domaniewski T, Buczko W.
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):710-3. PubMed ID: 14639091
    [Abstract] [Full Text] [Related]

  • 13. Effect of losartan on human platelet activation.
    Guerra-Cuesta JI, Montón M, Rodríguez-Feo JA, Jiménez AM, González-Fernández F, Rico LA, García R, Gómez J, Farré J, Casado S, López-Farré A.
    J Hypertens; 1999 Mar; 17(3):447-52. PubMed ID: 10100084
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Jiménez AM, Montón M, García R, Núñez A, Gómez J, Rico L, García-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farré J, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):406-12. PubMed ID: 11300653
    [Abstract] [Full Text] [Related]

  • 15. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats.
    Siragy HM, Carey RM.
    J Clin Invest; 1997 Jul 15; 100(2):264-9. PubMed ID: 9218502
    [Abstract] [Full Text] [Related]

  • 16. Losartan inhibits the adhesion of rat platelets to fibrillar collagen--a potential role of nitric oxide and prostanoids.
    Matys T, Chabielska E, Pawlak R, Kucharewicz I, Buczko W.
    J Physiol Pharmacol; 2000 Dec 15; 51(4 Pt 1):705-13. PubMed ID: 11192943
    [Abstract] [Full Text] [Related]

  • 17. AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries.
    Thorup C, Kornfeld M, Goligorsky MS, Moore LC.
    J Am Soc Nephrol; 1999 Jan 15; 10 Suppl 11():S220-4. PubMed ID: 9892167
    [Abstract] [Full Text] [Related]

  • 18. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors.
    Maeso R, Navarro-Cid J, Muñoz-García R, Rodrigo E, Ruilope LM, Lahera V, Cachofeiro V.
    Hypertension; 1996 Dec 15; 28(6):967-72. PubMed ID: 8952584
    [Abstract] [Full Text] [Related]

  • 19. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis.
    Madrid MI, García-Salom M, Tornel J, De Gasparo M, Fenoy FJ.
    Am J Physiol; 1997 Nov 15; 273(5):R1676-82. PubMed ID: 9374809
    [Abstract] [Full Text] [Related]

  • 20. Interactions between nitric oxide and angiotensin II on renal cortical and papillary blood flow.
    Madrid MI, García-Salom M, Tornel J, de Gasparo M, Fenoy FJ.
    Hypertension; 1997 Nov 15; 30(5):1175-82. PubMed ID: 9369273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.